Artemis Pharmaceuticals GMBH
This article was originally published in Start Up
Artemis's scientific co-founder, Christiane Nusslein-Volhard, PhD, of the Max Planck Institute, is one of the world's experts and the pioneer in the genetic study of zebra fish. Nusslein-Volhard, who retains her academic position, brings this expertise to Artemis, which is putting a commercial spin on the research. The start-up is knocking out genes in the fish and relating mutations to diseases seen in other vertebrates.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.